aibio
Debt Financing ·
Lexicon signs up to $100 million loan with Hercules Capital
Lexicon signed a loan of up to $100 million from Hercules in three tranches. The first $55 million was funded at closing, and Hercules receives warrants at $1.59 a share.
LXRX Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals (LXRX) news LXRX reverse split news
Latest Lexicon Pharmaceuticals news
- Listings
Lexicon Pharmaceuticals moves to Nasdaq Capital Market to get more time on $1 bid rule
Lexicon gets until December 30, 2025 to regain the $1 minimum bid price and moves to the Nasdaq Capital Market on July 7, 2025, with a reverse split on the table if needed.
Lexicon Pharmaceuticals annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $49.8 million | $31.1 million |
| Research and development | $61.1 million | $84.5 million |
| Net income (loss) | -$50.3 million | -$200.4 million |
| Cash from operations | -$67.9 million | -$178.8 million |
| Cash and equivalents | $34.3 million | $66.7 million |
| Short-term investments | $61.9 million | $171.3 million |
Questions about Lexicon Pharmaceuticals
Did Lexicon Pharmaceuticals do a reverse stock split?
Our latest story on this, dated Jul 3, 2025: "Lexicon Pharmaceuticals moves to Nasdaq Capital Market to get more time on $1 bid rule". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals, Inc. trades under the ticker LXRX on NASDAQ.
Where is Lexicon Pharmaceuticals listed?
Lexicon Pharmaceuticals, Inc. is listed on NASDAQ.
What is the SEC CIK of Lexicon Pharmaceuticals?
The SEC Central Index Key (CIK) for Lexicon Pharmaceuticals, Inc. is 1062822. Its filings are on SEC EDGAR.
How many shares does Lexicon Pharmaceuticals have outstanding?
444,955,934 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Lexicon Pharmaceuticals listed under?
Our directory records Lexicon Pharmaceuticals, Inc. under United States.
What does Lexicon Pharmaceuticals do?
Our directory classifies Lexicon Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Lexicon Pharmaceuticals?
The ISIN recorded for Lexicon Pharmaceuticals, Inc. is US5288723027.
Does aibio.space cover Lexicon Pharmaceuticals?
aibio.space lists Lexicon Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Lexicon Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as DE.
What was Lexicon Pharmaceuticals's revenue last year?
$49.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Lexicon Pharmaceuticals profitable?
Lexicon Pharmaceuticals, Inc. reported a net loss of $50.3 million for the fiscal year ended Dec 31, 2025, and used $67.9 million of cash in operations, per its annual report to the SEC.
How much does Lexicon Pharmaceuticals spend on research and development?
$61.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Lexicon Pharmaceuticals have?
$190.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Lexicon Pharmaceuticals (LXRX) stock news?
Our latest story on Lexicon Pharmaceuticals, dated May 4, 2026: "Lexicon signs up to $100 million loan with Hercules Capital". Lexicon signed a loan of up to $100 million from Hercules in three tranches. The first $55 million was funded at closing, and Hercules receives warrants at $1.59 a share. Source.
Investor discussion: Lexicon Pharmaceuticals
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,5.03,5.07,9.01). Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 1.01,5.07,9.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Stock chart
SEC filings and registration
- SEC name
- Lexicon Pharmaceuticals, Inc.
- CIK
- 1062822
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- LXRX (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS, TX, 77381
- Phone
- 2818633000
- Shares outstanding
- 444,955,934 as of 2026-08-03 (10-Q filed 2026-08-06)
- Former names
- LEXICON PHARMACEUTICALS, INC./DE; LEXICON GENETICS INC/TX
Recent filings
Listing details
- Company
- Lexicon Pharmaceuticals, Inc.
- Ticker
- LXRX
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US5288723027
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction